In contrast, a retrospective study done by Jeanson A et al. assessing the effectiveness of ICI in advanced NSCLC with 282 patients, of which 162 were harboring KRAS mutation, showed no significant benefit of ICI, nor PFS or OS [38]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.